DEBuT-LRP: Intravascular Identification and Drug-Eluting Balloon Treatment of Vulnerable Lipid-Rich Plaques
Study Details
Study Description
Brief Summary
Rationale: Two-thirds of intracoronary thrombi causing acute coronary syndrome (ACS) result from rupture of lipid-rich plaques (LRP). After treatment of the culprit lesion in ACS patients, additional LRPs are found in approximately 50% of patients. Near infrared spectroscopy (NIRS) combined with intracoronary ultrasound (IVUS) can identify these vulnerable plaques during coronary angiography (CAG) and is able to assess plaque characteristics and the lipid-core burden index in a 4mm segment (LCBImm4). It is currently unknown whether treatment of LRPs leads to plaque stabilization, potentially reducing the number of subsequent ACS. We hypothesize that LRPs can be treated with balloons coated with an antiproliferative drug (i.e. drug-eluting balloons; DEB) to deliver selective pharmacotherapeutic treatment to halt the local atherosclerotic process and subsequently reduce the risk for atherosclerotic events.
Objectives: To determine the change in plaque characteristics of non-culprit LRPs, as measured with IVUS/NIRS, after treatment with DEB in patients with ACS.
Study design: Prospective single-arm clinical trial
Study population: Patients with non-ST-elevation acute coronary syndromes
Intervention: If a LRP is detected with IVUS/NIRS, it will be treated with DEB. In case multiple LRPs are detected, only one will be treated.
Main study endpoints: The difference in LCBImm4 between baseline and 9 months of plaques treated with DEB.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Drug-eluting balloon treatment Drug-eluting balloon (DEB) treatment of lipid-rich plaque |
Device: Drug-eluting balloon treatment
Drug-eluting balloon (DEB) treatment of lipid-rich plaque
|
Outcome Measures
Primary Outcome Measures
- LCBImm4 difference of DEB-treated LRPs [9 months]
The difference in LCBImm4 between baseline and 9 months follow-up of lipid-rich plaques treated with drug-eluting balloon, as measured with near-infrared spectroscopy (NIRS).
Secondary Outcome Measures
- The change in lipid-core burden index in a 4 mm segment (LCBImm4) as measured with IVUS + NIRS from baseline to 9 month follow-up in identified additional LRPs that are not treated with DEB. [9 months]
- Rate of flow-limiting dissections necessitating bail-out stent implantation; [9 months]
- Rate of periprocedural myocardial infarction; [9 months]
- Rate of LRP lesion failure (defined as cardiac death, myocardial infarction, or ischemia-driven revascularization related to an identified non-culprit LRP lesion up to one-year follow-up); [1 year]
- Patient-oriented composite outcomes, defined as all-cause mortality, myocardial infarction, or any repeat revascularization up to one-year follow-up; [1 year]
- Additional IVUS + NIRS lesion characteristics: plaque volume [9 months]
- Additional IVUS + NIRS lesion characteristics: minimal lumen area [9 months]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patient has an acute coronary syndrome without ST-segment elevation on the ECG (NSTE-ACS), including non-ST-elevation myocardial infarction and unstable angina pectoris, defined according to the Fourth Universal Definition of Myocardial Infarction.
-
An invasive revascularization strategy for NSTE-ACS with PCI is chosen.
Exclusion Criteria:
- Angiographic exclusion criteria:
-
Previous coronary artery bypass-grafting;
-
Presence of a chronic total occlusion;
-
Too many (complex) coronary lesions requiring staged PCI procedure(s);
-
Procedural complication of the index PCI;
- Clinical exclusion criteria:
-
Unstable patients (the presence of cardiogenic shock, need for intubation, need for inotropes);
-
Patients with ST-segment elevations on the ECG requiring immediate primary PCI;
-
Body weight > 250 kg;
-
Known renal insufficiency (estimated Glomerular Filtration Rate [eGFR] <30 mL/min/1.73m2 or subject on dialysis);
-
Hypersensitivity or allergy to contrast with inability to properly pre-hydrate;
-
Presence of a comorbid condition with a life expectancy of less than one year;
-
Participation in another trial;
-
Subject is belonging to a vulnerable population (per investigator's judgment, e.g., subordinate hospital staff) or is unable to read or write.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Amsterdam UMC, location AMC | Amsterdam | Netherlands | 1105AZ |
Sponsors and Collaborators
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- DEBuT-LRP